'From the start, our corporate mission has been to make regenerative medicine the standard of care. We continue to be true to this goal, and it's the key reason why we pursued this opportunity.'  - Octane Medical Group CEO Timothy Smith.

“从一开始，我们的公司使命就是使再生医学成为护理的标准。我们继续忠于这一目标，这是我们追求这一机会的关键原因。”-辛烷医疗集团首席执行官蒂莫西·史密斯。

Kingston, Ontario, and Melsungen, Germany--(Newsfile Corp. - June 7, 2024) - Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global orthobiologics business from its long-term partner B. Braun. The acquisition, consisting of the two companies TETEC AG in Germany and Aesculap Biologics, LLC.

安大略省金斯敦和德国梅尔桑根——（新闻文件公司——2024年6月7日）——辛烷医疗集团通过其新成立的辛烷生物治疗公司（BioTx）从其长期合作伙伴B.Braun手中收购了全球正生物制剂业务的100%股份。此次收购由德国的两家公司TETEC AG和Aesculap Biologics，LLC组成。

in the United States, establishes Octane as an international leader in regenerative medicine..

在美国，辛烷确立了再生医学的国际领先地位。。

The orthobiologics platform currently includes two products: NOVOCART 3D, which implants a collagen-based matrix scaffold seeded with cartilage cells into the defective area, and NOVOCART Inject, an injectable mixture of cartilage cells and PEG-albumin-hyaluronic acid hydrogel.

orthobiologics平台目前包括两种产品：NOVOCART 3D，它将基于胶原蛋白的基质支架与软骨细胞一起植入缺陷区域，以及NOVOCART Injection，一种软骨细胞和PEG-白蛋白-透明质酸水凝胶的可注射混合物。

'Octane previously partnered with B. Braun for more than 10 years to scale up production of living-tissue orthopedic implants,' said Timothy Smith, CEO and co-founder of Octane, a global leader in regenerative medicine with the most advanced technologies in cell therapy, spinal implants, medical imaging and bioelectricity.

Octane首席执行官兼联合创始人蒂莫西·史密斯（TimothySmith）说，Octane之前与B.Braun合作了10多年，以扩大活组织骨科植入物的生产。Octane是再生医学领域的全球领导者，拥有细胞治疗、脊柱植入物、医学成像和生物电领域最先进的技术。

'This acquisition brings the NOVOCART autologous chondrocyte implantation (ACI) technology for articular cartilage repair into the innovation portfolio at Octane, giving the company full ownership of the NOVOCART value chain - from design development, clinical trials and manufacturing through to sales, distribution and clinical use.'.

“此次收购将用于关节软骨修复的NOVOCART自体软骨细胞植入（ACI）技术纳入辛烷的创新组合，使该公司完全拥有NOVOCART价值链的所有权-从设计开发，临床试验和制造到销售，分销和临床使用。”。

Pivotally, the acquisition also allows Octane to leverage the automated cell production capabilities of its Cocoon bioreactor to expand and accelerate manufacturing of NOVOCART articular cartilage implants. This positions Octane to become the first ACI therapy provider to significantly reduce production costs, while increasing consistency, quality, and scalability thanks to Cocoon's automated manufacturing platform..

重要的是，此次收购还使辛烷能够利用其Cocoon生物反应器的自动化细胞生产能力，扩大和加速NOVOCART关节软骨植入物的制造。这使辛烷成为第一家显着降低生产成本的ACI治疗供应商，同时由于Cocoon的自动化制造平台，提高了一致性，质量和可扩展性。。

Cocoon, a first-of-its-kind automated production system for personalized cell therapies, manufactures cells in a precisely controlled bioreactor for applications in a diverse range of critical diseases and conditions. Octane's goal is to transition NOVOCART from its current manual production process to full automation with Cocoon..

Cocoon是第一个用于个性化细胞疗法的自动化生产系统，它在精确控制的生物反应器中制造细胞，用于各种关键疾病和条件。辛烷的目标是将NOVOCART从目前的手动生产过程过渡到Cocoon的全自动化。。

'The combination of NOVOCART and Cocoon will lead to improved quality, greater capacity and operational flexibility, plus higher product margins,' said Ian Grant, COO and co-founder of Octane. 'This will, in turn, further enable efficient international turnkey expansion, particularly into the European Union and North American markets.'.

Octane联合创始人、首席运营官伊恩·格兰特（IanGrant）说，NOVOCART和Cocoon的结合将提高产品质量、产能和运营灵活性，并增加产品利润率反过来，这将进一步实现高效的国际交钥匙扩张，特别是进入欧盟和北美市场。”。

Dr. Jens von Lackum, a member of the B. Braun Board and chairman of the Executive Board of Aesculap AG, stated that the complete sale of the orthobiologics business to Octane is part of Aesculap's strategic focus on the Operating Room to provide innovative surgical solutions for our key customers.

B.Braun董事会成员兼Aesculap AG执行董事会主席Jens von Lackum博士表示，将orthobiologics业务完全出售给Octane是Aesculap在手术室的战略重点，为我们的关键客户提供创新的手术解决方案。

'We are proud of the impressive achievements our highly skilled employees have realized over the past years and are grateful to have had the opportunity to protect and improve the health of patients in need of cartilage repair. Moving forward, we are pleased that the product and production know-how is now bundled at Octane, forming the basis for even more patient-centric innovations.

“我们为我们的高技能员工在过去几年中取得的令人印象深刻的成就感到骄傲，并感谢有机会保护和改善需要软骨修复的患者的健康。展望未来，我们很高兴该产品和生产专有技术现已捆绑在辛烷值，为更多以患者为中心的创新奠定了基础。

With this in mind, we believe that our long-term partner Octane and its employees have a strong potential to further scale the business and make NOVOCART products available to even more patients.'.

考虑到这一点，我们相信我们的长期合作伙伴Octane及其员工有很大的潜力进一步扩大业务规模，并为更多患者提供NOVOCART产品。”。

'With over 120,000 square feet (11,000 square meters) across three sites located in Canada, U.S.A and Germany, Octane will be able to leverage shared efficiencies for product development, GMP (good manufacturing practice) production, regulatory submissions and clinical rollout,' said Smith. 'We are well positioned, thanks to our multidisciplinary team, to commercialize our portfolio in multiple key market sectors.

史密斯说：“辛烷在加拿大、美国和德国的三个工厂拥有超过120000平方英尺（11000平方米）的面积，将能够在产品开发、GMP（良好生产规范）生产、监管提交和临床推广方面利用共享效率。”多亏了我们的多学科团队，我们处于有利地位，可以在多个关键市场领域将我们的投资组合商业化。

Driving forward, Octane will continue to focus on stellar talent, exceptional science and game-changing products.'.

在前进的道路上，辛烷将继续专注于杰出的人才、卓越的科学和改变游戏规则的产品。”。

ABOUT OCTANE MEDICAL GROUP

关于辛烷医疗集团

Headquartered in Ontario, Canada with locations in the United States and Europe, Octane is a global group of companies with the most advanced bioprocesses, biomaterials and bioreactors for regenerative medicine. We power transformative healthcare with game-changing technologies that we develop and turn into proof-of-concept platforms.

Octane总部位于加拿大安大略省，在美国和欧洲设有办事处，是一家全球集团公司，拥有用于再生医学的最先进的生物工艺、生物材料和生物反应器。我们通过开发改变游戏规则的技术来推动变革性医疗保健，并将其转变为概念验证平台。

These innovations are advanced into production within our market-specific Octane ventures and then launched for commercialization with our global partners. Today, our Octane ventures include Octane Clinical Systems, Octane Orthobiologics, Octane Exo, Octane Biotech and Octane Biotherapeutics (BioTx)..

这些创新在我们针对特定市场的辛烷值企业中投入生产，然后与我们的全球合作伙伴一起推出商业化。今天，我们的辛烷值企业包括辛烷值临床系统、辛烷值正生物制剂、辛烷值Exo、辛烷值生物技术和辛烷值生物治疗学（BioTx）。。

At Octane, our goal is to make regenerative medicine the standard of care. For more information, visit www.octaneco.com.

在Octane，我们的目标是使再生医学成为护理的标准。有关更多信息，请访问www.octaneco.com。

ABOUT B. Braun

关于B.Braun

B. Braun is one of the world's leading medical technology companies. With 63,000 employees, B. Braun is a true partner developing smart solutions and setting standards to drive advancements in health care. In 2023, the B. Braun Group recorded 8.8 billion euros in sales. For more information visit www.bbraun.com..

B、 博朗是世界领先的医疗技术公司之一。B.Braun拥有63000名员工，是开发智能解决方案和制定标准以推动医疗保健进步的真正合作伙伴。2023年，布劳恩集团的销售额达到88亿欧元。有关更多信息，请访问www.bbraun.com。。

For media interviews:

对于媒体采访：

Chris Miranda

克里斯·米兰达

613-634-6345

613-634-6345

chris.miranda@octaneco.com

chris.miranda@octaneco.com

For partnership inquiries

对于合作伙伴查询

Christine Bossak

Christine Bossak女士

+495661711635

+495661711635

christine.bossak@bbraun.com

christine.bossak@bbraun.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/212071

要查看此新闻稿的源版本，请访问https://www.newsfilecorp.com/release/212071